News
SaNOtize faces increased demand and is now seeking to raise funds to support production expansion
SaNOtize reports that NONS sales in Q3 2021 were $5M and are projected to exceed $9M by the end of 2021. SaNOtize anticipates 2022 revenues will be $70-100M - the timing of approvals in various countries is a key driver of sales volume. With healthy contribution margins, the company believes it could be cash flow positive by the end of 2022. The company is now raising additional funds through OurCrowd platform; To read more about this investment opportunity, here is a link to SaNOtize's company page.
Read MoreBNN Bloomberg: An Interview with Dr. Gilly Regev of SaNOtize
U.K. clinical trials for Vancouver’s SaNOtize have confirmed that its nasal spray reduced SARS-CoV-2 log viral load by more than 95 per cent in infected participants within 24 hours of treatment, and by more than 99 per cent in 72 hours.
Read MoreFEATURED PRODUCTS
